INVENTOR SEARCH

=> fil capl; d que nos 144
FILE 'CAPLUS' ENTERED AT 15:08:14 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 15 Jun 2007 VOL 146 ISS 26
FILE LAST UPDATED: 14 Jun 2007 (20070614/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L8 STR
L11 625 SEA FILE=REGISTRY SSS FUL L8
L21 1 SEA FILE=CAPLUS ABB=ON US2005-561415/AP
L35 STR
L38 STR
L39 STR
L42 151 SEA FILE=REGISTRY SUB=L11 SSS FUL (L35 OR L38 OR L39)
L43 5 SEA FILE=CAPLUS ABB=ON L42
L44 1 SEA FILE=CAPLUS ABB=ON L21 OR (L21 AND L43)

=> d ibib ed abs hitstr 144

L44 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:143245 CAPLUS Full-text
DOCUMENT NUMBER: 142:93527
TITLE: Preparation of benzophenone derivatives as HSP90 inhibitors for treatment of tumor
INVENTOR(S): Hara, Shinji; Nakagawa, Hiroshi; Kanda, Yutaka; Nakashima, Takayuki; Goga, Shiro; Kajita, Jiro; Saito, Junichi; Shiotsu, Yukimasa; Akinaga, Shiro
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 206 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2005000779	A1	20050106	WO 2004-JP8492	20040611
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004251949	A1	20050106	AU 2004-251949	20040611
CA 2529371	A1	20050106	CA 2004-2529371	20040611
EP 1642890	A1	20060405	EP 2004-736032	20040611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1791585	A	20060621	CN 2004-80016007	20040611
US 20070032532	A1	20070208	US 2005-561415	20051215
PRIORITY APPLN. INFO.:			JP 2003-169605	A 20030613
			WO 2004-JP8492	W 20040611

OTHER SOURCE(S): MARPAT 142:93527
ED Entered STN: 07 Jan 2005
GI

AB The title compds. I [wherein n = 1-10; R1 = H, OH, CN, etc., R2 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclyl; R3 and R5 = independently H, (un)substituted alkyl, alkenyl, etc.; R4 and R6 = independently H, CN, halo, CN, etc.] or prodrugs or pharmaceutically acceptable salts thereof are prepared as heat-shock proteins (HSP) 90 inhibitors. For example, the compound II was prepared in a multi-step synthesis. II inhibited 430% human HSP90 at the concentration of 10 μM. I are useful as antitumor agents (no data).
IT 819811-92-2P 819812-04-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of benzophenone derivs. as HSP90 inhibitors for treatment of tumor)
RN 819811-92-2 CAPLUS
CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-2-ethyl-3,5-dihydroxy-4-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819810-89-4 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-4-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]benzoyl]- (9CI) (CA INDEX NAME)



IT 819810-89-4P 819810-92-9P 819810-93-0P
819810-95-2P 819810-96-3P 819811-00-2P
819811-01-3P 819811-02-4P 819811-03-5P
819811-04-6P 819811-05-7P 819811-07-9P
819811-09-1P 819811-10-4P 819811-11-5P
819811-12-6P 819811-14-8P 819811-15-9P
819811-16-0P 819811-17-1P 819811-18-2P
819811-19-3P 819811-20-6P 819811-21-7P
819811-22-8P 819811-23-9P 819811-24-0P
819811-26-2P 819811-27-3P 819811-28-4P
819811-29-5P 819811-33-1P 819811-34-2P
819811-35-3P 819811-40-0P 819811-43-3P
819811-45-5P 819811-46-6P 819811-47-7P
819811-48-8P 819811-54-6P 819811-55-7P
819811-56-8P 819811-57-9P 819811-58-0P
819811-59-1P 819811-60-4P 819811-61-5P
819811-62-6P 819811-63-7P 819811-64-8P
819811-65-9P 819811-66-0P 819811-67-1P
819811-68-2P 819811-69-3P 819811-70-6P
819811-71-7P 819811-72-8P 819811-73-9P
819811-74-0P 819811-75-1P 819811-76-2P
819811-77-3P 819811-78-4P 819811-79-5P
819811-80-8P 819811-81-9P 819811-82-0P
819811-83-1P 819811-84-2P 819811-85-3P
819811-86-4P 819811-87-5P 819811-88-6P
819811-89-7P 819811-90-0P 819811-91-1P
819811-93-3P 819811-94-4P 819811-95-5P
819811-96-6P 819811-97-7P 819811-98-8P
819811-99-9P 819812-00-5P 819812-01-6P
819812-02-7P 819812-03-8P 819812-05-0P
819812-06-1P 819812-07-2P 819812-09-4P
819812-10-7P 819812-11-8P
819812-12-9P 819812-13-0P 819812-14-1P
819812-15-2P 819812-16-3P 819812-17-4P
819812-18-5P 819812-19-6P 819812-20-9P

819812-21-0P 819812-22-1P 819812-23-2P
819812-24-3P 819812-25-4P 819812-26-5P
819812-27-6P 819812-28-7P 819812-29-8P
819812-36-7P 819812-37-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzophenone derivs. as HSP90 inhibitors for treatment of tumor)
RN 819812-22-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-4-[4-methoxybenzoyl]-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 819812-37-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-N,5-dihydroxy-N,N-bis(2-hydroxyethyl)-4-[4-methoxybenzoyl]- (9CI) (CA INDEX NAME)



RN 819812-36-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-4-[4-methoxybenzoyl]-N-methyl- (9CI) (CA INDEX NAME)





RN 819810-96-3 CAPLUS
CN Piperazine, 1-(2-cyanophenyl)-4-[(2-ethyl-3,5-dihydroxy-6-[(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-00-2 CAPLUS
CN 3-Piperidinol, 1-[[2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-01-3 CAPLUS
CN 3-Piperidinemethanol, 1-[[2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-02-4 CAPLUS
CN 3-Piperidinecarboxamide, 1-[[2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-02-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-04-6 CAPLUS
CN 2-Pyrrolidinol, 1-[[2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-05-7 CAPLUS
CN Benzeneacetamide, N-(2,3-dihydroxypropyl)-2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 819811-07-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(3-

pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 819811-09-1 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 819811-10-4 CAPLUS
CN 4-Piperidinol, 1-[[2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]phenyl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 819811-11-5 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]phenyl]acetyl]-4-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 819811-12-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-[4-methoxybenzoyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-14-8 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 819811-15-9 CAPLUS
CN Piperazine, 1-acetyl-4-[[2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-26-0 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]phenyl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 819811-27-1 CAPLUS

ST Isoquinolium, 2 [2 ethyl 3,5 dihydroxy 4 (4 methoxybenzoyl)phenyl] acetyl] 1,2,3,4 tetrahydro 6,7 dimethoxy (9CI) (CA INDEX NAME)



RN 615811-16-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-N-(2-furanylmethyl)-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 615811-19-4 CAPLUS
CN 1-Piperazineethanol, 4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 615811-20-7 CAPLUS
CN Piperazine, 1-[[2-(2,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxyphenyl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)





RN 615811-21-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 615811-22-8 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 615811-23-9 CAPLUS
CN Morpholine, 4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 615811-24-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-[3-(2-oxo-1-

pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 615811-26-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxy-1-(hydroxymethyl)ethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 615811-27-3 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 615811-14-6 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 615811-25-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 615811-33-1 CAPLUS
CN Isoquinoline, 2-[[2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxyphenyl]acetyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 615811-16-2 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)phenyl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 615811-35-3 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619811-40-2 CAPLUS
CN 4-Piperidinemethanol, 1-[(2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]phenyl)acetyl]- (9CI) (CA INDEX NAME)



RN 619811-43-5 CAPLUS
CN Piperazinone, 1-(3-chlorophenyl)-4-[[2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 619811-45-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-4-(4-fluorobenzoyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619811-46-8 CAPLUS
CN Piperidine, 1-[(2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]phenyl)acetyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 619811-47-9 CAPLUS
CN Piperazinone, 4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxyphenoxy)phenyl]acetyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 619811-49-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-N-(2-furanylmethyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-4-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 619811-54-8 CAPLUS
CN Piperazinone, 4-[(2-benzoyl-6-ethyl-3,5-dihydroxyphenyl)acetyl]-1-(2-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 619811-55-9 CAPLUS
CN Benzeneacetamide, 2-benzoyl-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 619811-56-8 CAPLUS
CN Benzeneacetamide, 2-benzoyl-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619811-57-0 CAPLUS
CN 4-Piperidinemethanol, 1-[(2-benzoyl-6-ethyl-3,5-dihydroxyphenyl)acetyl]- (9CI) (CA INDEX NAME)



RN 619811-58-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-4-(3-hydroxybenzoyl)-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619811-59-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)-N,N-bis(2-hydroxyethyl)-



RN 619811-60-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxyphenoxy)-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619811-61-6 CAPLUS
CN Piperazinone, 4-[[2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxyphenyl]acetyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 619811-62-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(3-hydroxy-4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 619811-63-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(3-methoxy-4-methoxyphenoxy)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-64-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(5-fluoro-4-methoxybenzoyl)-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-65-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(5-fluoro-4-methoxybenzoyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-66-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-67-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-68-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-[4-hydroxy-3-methoxybenzoyl]-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-69-3 CAPLUS
CN Benzeneacetamide, 2-[4-(difluoromethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-70-6 CAPLUS
CN Benzeneacetamide, 2-[4-(difluoromethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-71-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(3-hydroxy-4-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 819811-72-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(3-hydroxy-4-methylbenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-73-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)-6-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-74-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(methylamino)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-75-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-[4-(methylsulfanyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-76-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(methylsulfonyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-77-3 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[[3-ethyl-2,5-dihydroxy-4-[4-methoxybenzoyl]phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 819811-78-4 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)



RN 819811-79-5 CAPLUS

CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-N-(2-furanylmethyl)-3,4-dihydroxy-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-40-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 819811-41-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-[3-(2-hydroxyethoxy)-4-methoxybenzoyl]-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-42-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-methoxy-3-(2-methoxyethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-43-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-44-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-hydroxy-3-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-45-3 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxy-3-methoxybenzoyl)-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-46-4 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[4-(methylsulfonyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-47-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-[4-(2-hydroxyethoxy)-3-methoxybenzoyl]-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-48-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-methoxy-3-(2-morpholinylethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-49-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-90-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 819811-91-1 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-N-[2-(dimethylamino)ethyl]-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-92-2 CAPLUS
CN Benzeneacetamide, N-[2-(diethylamino)ethyl]-2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-96-6 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 619811-95-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-[4-methoxybenzoyl]-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 619811-96-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(3-hydroxypropyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619811-97-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 619811-98-8 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-4-ethyl-3,5-dihydroxy-N-(2-

hydroxypropyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619811-99-9 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 619812-00-5 CAPLUS
CN Benzeneacetamide, 2-(4-ethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 619812-01-6 CAPLUS
CN Benzeneacetamide, 2-(4-ethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619812-02-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-[4-(2-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 619812-03-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 619812-05-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-[(2-hydroxyethoxy)(4-methoxybenzoyl]-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619812-06-1 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-N-[3-(dimethylamino)propyl]-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619812-07-2 CAPLUS
CN Benzeneacetamide, 2-[3-(dimethylamino)propyl]-2-ethyl-3,4-dihydroxy-5-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619812-08-3 CAPLUS
CN Benzeneacetamide, N-[2-(diethylamino)ethyl]-2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619812-09-4 CAPLUS
CN Benzeneacetamide, N-[2-(diethylamino)ethyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619812-10-7 CAPLUS
CN Piperidine, 1-[[2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxyphenyl]acetyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 619812-11-8 CAPLUS
CN Piperidine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 819812-11-9 CAPLUS
CN Benzeneacetamide, 2-(4-ethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 819812-13-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-6-[4-(1-methylethoxy)benzoyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 819812-14-2 CAPLUS
CN Benzeneacetamide, 2-bromo-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-15-3 CAPLUS
CN Benzeneacetamide, 2-acetyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-16-4 CAPLUS
CN Benzeneacetamide, 2-[3,4-bis(2-methoxyethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-17-5 CAPLUS
CN Benzeneacetamide, 2-[3,4-bis(2-methoxyethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819813-18-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-(3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 819812-19-4 CAPLUS
CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 819812-20-7 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-N-[2-(dimethylamino)ethyl]-6-ethyl-3,5-dihydroxy-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 819812-21-8 CAPLUS
CN Benzeneacetamide, N-(2-(dimethylamino)ethyl)-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 819813-31-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-[4-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-22-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-23-0 CAPLUS
CN Benzeneacetamide, 2-[3,4-difluorobenzoyl]-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-25-2 CAPLUS
CN Benzeneacetamide, 2-(3,4-difluorobenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-26-3 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-6-[4-(1-piperidinyl)ethoxy]benzoyl]-N-(2-piperidinylethyl)- (9CI) (CA INDEX NAME)



RN 819812-27-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-5,6-dihydroxy-N,N-bis(2-methoxyethyl)-3-(3-methoxy-4-[4-(4-morpholinylacetyl)-1-piperazinyl]methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 819813-25-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-5,6-dihydroxy-N,N-bis(2-methoxyethyl)-4-(3-methoxy-4-[3-(4-morpholinylacetyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 819813-29-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-5,6-dihydroxy-N,N-bis(2-methoxyethyl)-4-(3-methoxy-4-[4-(4-methyl-1-piperazinyl)-2-oxoethoxy]benzoyl)- (9CI) (CA INDEX NAME)



RN 819813-36-7 CAPLUS
CN Benzeneacetamide, 2-(1,3-benzodioxol-5-ylcarbonyl)-6-ethyl-5,6-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819813-37-8 CAPLUS
CN Benzeneacetamide, 2-(1,3-benzodioxol-5-ylcarbonyl)-6-ethyl-5,6-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



IT 819812-93-6P 819813-12-2P 819813-17-7P
819813-18-8P 819813-30-6P 819813-40-6P
819813-45-1P 819813-47-3P 819813-48-4P
819813-49-5P 819813-50-8P 819813-51-9P
819813-54-4P 819813-57-7P 819813-58-8P
819813-59-9P 819813-60-2P 819813-61-1P
819813-62-2P 819813-63-3P 819813-64-4P
819813-67-7P 819813-69-9P 819813-70-2P
819813-76-8P 819813-79-1P 819813-80-4P
819813-81-5P 819813-82-6P 819813-83-7P
819813-84-8P
RL: RCT (Reactant), SPN (Synthetic preparation); PREP (Preparation), RACT (Reactant or reagent)
(intermediate, preparation of benzophenone deriv. as HSP90 inhibitors for treatment of tumor)
RN 819812-93-6 CAPLUS
CN Piperazine, 1-[(2-ethyl-6-[4-hydroxybenzoyl]-3,5-bis(2-propenyloxy)phenyl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 819813-12-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(4-hydroxybenzoyl)-N-(2-hydroxyethyl)-N-(2-

methoxyethyl)-3,5-bis(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 819813-17-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-N,N-bis(2-hydroxyethyl)-6-(3-hydroxy-4-methoxybenzoyl)-3,5-bis(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 819813-18-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(2-hydroxyethyl)-6-(2-hydroxy-4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 819813-30-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-N,N-bis(2-hydroxyethyl)-6-(3-hydroxy-4-methylbenzoyl)-3,5-bis(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 819813-40-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-N,N-bis(2-methoxyethyl)-6-[4-(methylsulfonyl)benzoyl]-3,5-bis(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 819815-45-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-N-(2-hydroxyethyl)-6-(4-methoxy-3-nitrobenzoyl)-N-[2-(4-morpholinyl)ethyl]-3,5-bis(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 819813-47-3 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-N-[2-(dimethylamino)ethyl]-6-ethyl-N-(2-methoxyethyl)-3,4-bis(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 819813-48-4 CAPLUS
CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-2-ethyl-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 819813-49-5 CAPLUS

CN Benzeneacetamide, 2-[4-(dimethylamino)ethyl]-2-ethyl-3,4-dimethoxybenzoyl]-6-methyl-N-(2-methoxyethyl)-3,5-bis(2-propynyloxy)- (9CI) (CA INDEX NAME)



RN 919813-62-8 CAPLUS

CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-N-(2-methoxyethyl)-N-[3-(4-morpholinyl)ethyl]-3,5-bis(2-propynyloxy)- (9CI) (CA INDEX NAME)



RN 919813-63-9 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]-3,5-bis(2-propynyloxy)- (9CI) (CA INDEX NAME)



RN 919813-64-0 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-(4-hydroxy-3-methoxybenzoyl)-N,N-bis(2-methoxyethyl)-3,5-bis(2-propynyloxy)- (9CI) (CA INDEX NAME)



RN 919813-67-3 CAPLUS

CN Benzeneacetamide, 2-ethyl-N,N-bis(2-methoxyethyl)-6-(2-methoxy-4-[2-(4-morpholinyl)ethoxy]benzoyl)-3,5-bis(2-propynyloxy)- (9CI) (CA INDEX NAME)



RN 919813-68-4 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-[4-(2-hydroxyethoxy)-3-methoxybenzoyl]-N,N-bis(2-methoxyethyl)-3,5-bis(2-propynyloxy)- (9CI) (CA INDEX NAME)



RN 919813-69-5 CAPLUS

CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-N-[3-(dimethylamino)propyl]-6-ethyl-N-(2-methoxyethyl)-3,5-bis(2-propynyloxy)- (9CI) (CA INDEX NAME)



RN 919813-60-9 CAPLUS

CN Benzeneacetamide, N-[3-(dimethylamino)propyl]-2-ethyl-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propynyloxy)- (9CI) (CA INDEX NAME)



RN 919813-61-1 CAPLUS

CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-2-(3,4-dimethoxybenzoyl)-6-ethyl-N-(2-methoxyethyl)-3,5-bis(2-propynyloxy)- (9CI) (CA INDEX NAME)



RN 919813-62-9 CAPLUS

CN Benzeneacetamide, N-[2-(diethylamino)ethyl]-2-ethyl-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propynyloxy)- (9CI) (CA INDEX NAME)



RN 919813-63-0 CAPLUS

CN Piperidine, 1-[[2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-bis(2-propynyloxy)phenyl]acetyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 919813-66-6 CAPLUS

CN Piperidine, 1-[[6-ethyl-2-(4-methoxybenzoyl)-3,5-bis(2-propynyloxy)phenyl]acetyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 919813-57-2 CAPLUS

CN Benzeneacetamide, 2-bromo-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(methoxymethoxy)- (9CI) (CA INDEX NAME)



RN 919813-59-9 CAPLUS

CN Benzeneacetamide, N-(2-hydroxyethyl)-2-iodo-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(methoxymethoxy)- (9CI) (CA INDEX NAME)



RN 919813-70-2 CAPLUS

CN Benzeneacetamide, 2-acetyl-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(methoxymethoxy)- (9CI) (CA INDEX NAME)



RN 919813-56-7 CAPLUS

CN Benzeneacetamide, 2-ethyl-N,N-bis(2-methoxyethyl)-6-(3-methoxy-4-[2-(4-morpholinyl)ethoxy]benzoyl)-3,5-bis(2-propynyloxy)- (9CI) (CA INDEX NAME)



RN r1:r13-12-1 CAPLUS
CN Benzeneacetamide, 2-[4-(3-chloropropoxy)-2-methoxybenzoyl]-6-ethyl-N,N-bis[2-methoxyethyl]-3,5-bis(2-propenyloxy)- (9CI) (CA INDEX NAME)



AN 819812-84-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-N,N-bis(2-methoxyethyl)-4-[3-methoxy-4-[2-[4-(4-morpholinyl)-1-piperidinyl]ethoxy]benzoyl]-3,5-bis(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN r1:r13-81-5 CAPLUS
CN Benzeneacetamide, 2-[4-(3-chloropropoxy)-2-methoxybenzoyl]-6-ethyl-N,N-bis(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 819813-41-4 CAPLUS

CN Benzeneacetamide, 2-ethyl-N,N-bis(2-methoxyethyl)-4-[3-methoxy-4-[2-[4-morpholinyl]propoxy]benzoyl]-3,5-bis(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 819811-83-2 CAPLUS
CN Acetic acid, [4-[2-[3-[bis(2-methoxyethyl)amino]-2-oxoethyl]-6-ethyl-4,5-bis(2-propenyloxy)benzoyl]-2-methoxyphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN r1:r13-84-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[2-(4-methyl-1-piperazinyl)-2-oxoethoxy]benzoyl]-3,5-bis(2-propenyloxy) (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

BROAD STRUCTURE + TEXT

=> fil reg; d stat que l11; fil capl; d que nos l48;d que nos l51; s l48,l51 not l44
FILE 'REGISTRY' ENTERED AT 15:08:48 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3
DICTIONARY FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

L8 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L11 625 SEA FILE=REGISTRY SSS FUL L8

100.0% PROCESSED 5028 ITERATIONS 625 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 15:08:48 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2007 VOL 146 ISS 26
FILE LAST UPDATED: 14 Jun 2007 (20070614/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L8 STR
L11 625 SEA FILE=REGISTRY SSS FUL L8
L45 29025 SEA FILE=CAPLUS ABB=ON HEAT SHOCK/OBI OR HSP90/OBI OR HSP/OBI

L47 283 SEA FILE=CAPLUS ABB=ON L11
L48 1 SEA FILE=CAPLUS ABB=ON L47 AND L45

L8 STR
L11 625 SEA FILE=REGISTRY SSS FUL L8
L47 283 SEA FILE=CAPLUS ABB=ON L11
L49 166137 SEA FILE=CAPLUS ABB=ON ANTITUMOR AGENTS/CT
L50 484200 SEA FILE=CAPLUS ABB=ON NEOPLAS?/OBI
L51 8 SEA FILE=CAPLUS ABB=ON L47 AND (L49 OR L50)

L52 7 (L48 OR L51) NOT L44

=> d ibib ed abs hitstr 1-7

L52 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:845182 CAPLUS Full-text
DOCUMENT NUMBER: 145:241713
TITLE: Antitumor agents containing benzoyl compounds
INVENTOR(S): Kanda, Yutaka; Soga, Shiro; Nakashima, Takayuki; Nara, Shinji; Nakagawa, Hiroshi; Shiotsu, Yukimasa
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 61pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006088193	A1	20060824	WO 2006-JP302996	20060221

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2005-44845 A 20050221

OTHER SOURCE(S): MARPAT 145:241713

ED Entered STN: 24 Aug 2006

GI



I

AB Disclosed is a therapeutic agent for a tumor selected from a hematopoietic tumor and a solid tumor, comprising, as the active ingredient, a benzoyl compound represented by the general formula I or a prodrug or pharmacol. acceptable salt thereof: I wherein n is an integer of 1 to 5; R1 represents a substituted or unsubstituted lower alkoxy, a substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R3 and R5 independently represent a hydrogen atom, a substituted or unsubstituted lower alkyl or the like; R4 represents a hydrogen atom, a hydroxy or a halogen; and R6 represents a hydrogen atom, a halogen, a substituted or unsubstituted lower alkyl or the like. For example, the antitumor activity of a compound I (R1 = CON(CH2CH2OH)2; n = 1; R2 = p-methoxyphenyl; R3, R4, R5 = H; R6 = Et) was in vitro tested.

IT 819810-81-6 819810-82-7 819810-85-0
819810-89-4 819810-92-9 819810-93-0
819810-94-1 819810-95-2 819810-96-3
819810-97-4 819810-98-5 819810-99-6
819811-00-2 819811-01-3 819811-02-4
819811-03-5 819811-04-6 819811-05-7
819811-06-8 819811-07-9 819811-08-0
819811-09-1 819811-10-4 819811-11-5
819811-12-6 819811-14-8 819811-15-9
819811-16-0 819811-17-1 819811-18-2
819811-19-3 819811-20-6 819811-21-7
819811-22-8 819811-23-9 819811-24-0
819811-26-2 819811-27-3 819811-28-4

819811-29-5 819811-33-1 819811-34-2
819811-35-3 819811-40-0 819811-43-3
819811-45-5 819811-46-6 819811-47-7
819811-48-8 819811-54-6 819811-55-7
819811-56-8 819811-57-9 819811-58-0
819811-59-1 819811-60-4 819811-61-5
819811-62-6 819811-63-7 819811-64-8
819811-65-9 819811-66-0 819811-67-1
819811-68-2 819811-69-3 819811-70-6
819811-71-7 819811-72-8 819811-73-9
819811-74-0 819811-75-1 819811-76-2
819811-77-3 819811-78-4 819811-79-5
819811-80-8 819811-81-9 819811-82-0
819811-83-1 819811-84-2 819811-85-3
819811-86-4 819811-87-5 819811-88-6
819811-89-7 819811-90-0 819811-91-1
819811-92-2 819811-93-3 819811-94-4
819811-95-5 819811-96-6 819811-97-7
819811-98-8 819811-99-9 819812-00-5
819812-01-6 819812-02-7 819812-03-8
819812-04-9 819812-05-0 819812-06-1
819812-07-2 819812-08-3 819812-09-4
819812-10-7 819812-11-8 819812-12-9
819812-13-0 819812-14-1 819812-15-2
819812-16-3 819812-17-4 819812-18-5
819812-19-6 819812-20-9 819812-21-0
819812-22-1 819812-23-2 819812-24-3
819812-25-4 819812-26-5 819812-27-6
819812-28-7 819812-29-8 819812-36-7
819812-37-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor agents containing benzoyl compds.)

RN 819810-81-6 CAPLUS
CN Benzeneacetic acid, 2-benzoyl-6-ethyl-3,5-dihydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 819810-82-7 CAPLUS
CN Benzeneacetic acid, 2-ethyl-3,5-dihydroxy-6-(3-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 819810-85-0 CAPLUS
CN Benzeneacetic acid, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 819810-89-4 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 819810-92-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 819810-93-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 819810-94-1 CAPLUS
CN Benzeneacetic acid, 3,5-dihydroxy-2-iodo-6-(4-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 819810-95-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-methyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 819810-96-3 CAPLUS
CN Piperazine, 1-(2-cyanophenyl)-4-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819810-97-4 CAPLUS
CN Benzeneacetic acid, 3-hydroxy-2-(4-methoxybenzoyl)-5-(2-propenyloxy)-,

methyl ester (9CI) (CA INDEX NAME)



RN 819810-98-5 CAPLUS
CN Benzeneacetic acid, 3,5-dihydroxy-2-(4-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 819810-99-6 CAPLUS
CN Benzeneacetic acid, 3,5-dihydroxy-2-(4-hydroxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 819811-00-2 CAPLUS
CN 3-Piperidinol, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-01-3 CAPLUS
CN 3-Piperidinemethanol, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-02-4 CAPLUS
CN 3-Piperidinecarboxamide, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-03-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-04-6 CAPLUS
CN 3-Pyrrolidinol, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-05-7 CAPLUS
CN Benzeneacetamide, N-(2,3-dihydroxypropyl)-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 819811-06-8 CAPLUS
CN Benzeneacetic acid, 5-hydroxy-3-methoxy-2-(4-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 819811-07-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 819811-08-0 CAPLUS
CN Benzeneacetic acid, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 819811-09-1 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-

phenyl- (9CI) (CA INDEX NAME)



RN 819811-10-4 CAPLUS
CN 4-Piperidinol, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 819811-11-5 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 819811-12-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-14-8 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 819811-15-9 CAPLUS
CN Piperazine, 1-acetyl-4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-16-0 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 819811-17-1 CAPLUS
CN Isoquinoline, 2-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 819811-18-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-N-(2-furanylmethyl)-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 819811-19-3 CAPLUS
CN 1-Piperazineethanol, 4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-20-6 CAPLUS
CN Piperazine, 1-[[2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxyphenyl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 819811-21-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 819811-22-8 CAPLUS

CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 819811-23-9 CAPLUS
CN Morpholine, 4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-24-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 819811-26-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 819811-27-3 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 819811-28-4 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-29-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-33-1 CAPLUS
CN Isoquinoline, 2-[[2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxyphenyl]acetyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 819811-34-2 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)phenyl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 819811-35-3 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-40-0 CAPLUS
CN 4-Piperidinemethanol, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-43-3 CAPLUS
CN Piperazinone, 1-(3-chlorophenyl)-4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-45-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-46-6 CAPLUS
CN Piperidine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 819811-47-7 CAPLUS
CN Piperazinone, 4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 819811-48-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-N-(2-furanylmethyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 819811-54-6 CAPLUS
CN Piperazinone, 4-[(2-benzoyl-6-ethyl-3,5-dihydroxyphenyl)acetyl]-1-(2-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 819811-55-7 CAPLUS
CN Benzeneacetamide, 2-benzoyl-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-56-8 CAPLUS
CN Benzeneacetamide, 2-benzoyl-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-57-9 CAPLUS
CN 4-Piperidinemethanol, 1-[(2-benzoyl-6-ethyl-3,5-dihydroxyphenyl)acetyl]- (9CI) (CA INDEX NAME)



RN 819811-58-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(3-hydroxybenzoyl)-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-59-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-60-4 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-61-5 CAPLUS
CN Piperazinone, 4-[[2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxyphenyl]acetyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 819811-62-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(3-hydroxy-4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 819811-63-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(3-hydroxy-4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-64-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(3-fluoro-4-methoxybenzoyl)-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-65-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(3-fluoro-4-methoxybenzoyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-66-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-67-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-68-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(3-hydroxy-4-methoxybenzoyl)-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-69-3 CAPLUS
CN Benzeneacetamide, 2-[4-(difluoromethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-70-6 CAPLUS
CN Benzeneacetamide, 2-[4-(difluoromethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-71-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(3-hydroxy-4-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 819811-72-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(3-hydroxy-4-methylbenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-73-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)-6-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-74-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(methylthio)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-75-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-[4-(methylsulfonyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-76-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(methylsulfonyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-77-3 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 819811-78-4 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)



RN 819811-79-5 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-N-(2-furanylmethyl)-3,5-dihydroxy-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-80-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 819811-81-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-[3-(2-hydroxyethdxy)-4-methoxybenzoyl]-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-82-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-methoxy-3-(2-methoxyethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-83-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-84-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-hydroxy-3-

methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-85-3 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxy-3-methoxybenzoyl)-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-86-4 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[4-(methylsulfonyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-87-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-[4-(2-hydroxyethoxy)-3-methoxybenzoyl]-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-88-6 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[3-methoxy-4-(2-methoxyethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-89-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-90-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 819811-91-1 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-N-[2-(dimethylamino)ethyl]-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-92-2 CAPLUS
CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-93-3 CAPLUS
CN Benzeneacetamide, N-[2-(diethylamino)ethyl]-2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-94-4 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 819811-95-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 819811-96-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(3-hydroxypropyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-97-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 819811-98-8 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(3-hydroxypropyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-99-9 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 819812-00-5 CAPLUS
CN Benzeneacetamide, 2-(4-ethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-01-6 CAPLUS
CN Benzeneacetamide, 2-(4-ethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-02-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-[4-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-03-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-04-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-05-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-[4-(2-hydroxyethoxy)-3-methoxybenzoyl]-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-06-1 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-N-[3-(dimethylamino)propyl]-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-07-2 CAPLUS
CN Benzeneacetamide, N-[3-(dimethylamino)propyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-08-3 CAPLUS
CN Benzeneacetamide, N-[2-(diethylamino)ethyl]-2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-09-4 CAPLUS
CN Benzeneacetamide, N-[2-(diethylamino)ethyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-10-7 CAPLUS
CN Piperidine, 1-[[2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxyphenyl]acetyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 819812-11-8 CAPLUS
CN Piperidine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 819812-12-9 CAPLUS
CN Benzeneacetamide, 2-(4-ethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 819812-13-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-6-[4-(1-methylethoxy)benzoyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 819812-14-1 CAPLUS
CN Benzeneacetamide, 2-bromo-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-15-2 CAPLUS
CN Benzeneacetamide, 2-acetyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-16-3 CAPLUS
CN Benzeneacetamide, 2-[3,4-bis(2-methoxyethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-17-4 CAPLUS
CN Benzeneacetamide, 2-[3,4-bis(2-methoxyethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-18-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 819812-19-6 CAPLUS
CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 819812-20-9 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-N-[2-(dimethylamino)ethyl]-6-ethyl-3,5-dihydroxy-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 819812-21-0 CAPLUS
CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 819812-23-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-24-3 CAPLUS
CN Benzeneacetamide, 2-(3,4-difluorobenzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-25-4 CAPLUS
CN Benzeneacetamide, 2-(3,4-difluorobenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-26-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[2-(1-piperidinyl)ethoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-27-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[2-[4-(4-morpholinyl)-1-piperidinyl]ethoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-28-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[3-(4-morpholinyl)propoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-29-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[2-(4-methyl-1-piperazinyl)-2-oxoethoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-36-7 CAPLUS
CN Benzeneacetamide, 2-(1,3-benzodioxol-5-ylcarbonyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-37-8 CAPLUS
CN Benzeneacetamide, 2-(1,3-benzodioxol-5-ylcarbonyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:451630 CAPLUS Full-text
DOCUMENT NUMBER: 141:23557
TITLE: Preparation of (R)-2,3-benzodiazepines for the treatment of neutropenia.
INVENTOR(S): Harris, Herbert W.; Kucharik, Robert F.
PATENT ASSIGNEE(S): Vela Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004106601	A1	20040603	US 2002-309527	20021203
US 7022700	B2	20060404		
US 2004138210	A1	20040715	US 2003-728286	20031202
WO 2004050615	A2	20040617	WO 2003-US38634	20031203
WO 2004050615	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003302682	A1	20040623	AU 2003-302682	20031203
PRIORITY APPLN. INFO.:			US 2002-309527 A2	20021203

WO 2003-US38634 W 20031203
OTHER SOURCE(S): MARPAT 141:23557
ED Entered STN: 04 Jun 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = alkylhydrocarbyl, heteroalkyl; R2 = H, hydrocarbyl, wherein R1 and R2 may combine to form a carbocyclic or heterocyclic 5- or 6-membered ring; X = (R3)n; R3 = O-alkyl, OH, O-acyl, etc.; n = 1-3; R4, R5 = O-alkyl, OH, O-acyl, etc., wherein R4 and R5 may combine to form a 5-, 6-, 7-membered heterocyclic ring] and their pharmaceutically acceptable salts were prepared. For example, condensation-cyclization of diketone II, e.g., prepared from 3-methoxy-4-hydroxybenzoic acid in 7-steps, and hydrazine hydrate afforded racemic benzodiazepine III. In a 16-day study of neutrophil production in rats, one example of compound I, e.g., R-tofisopam, significantly increased neutrophil levels in a dose-dependant manner. Compds. I are claimed useful for increasing the production of neutrophils.

IT 618056-34-1P, 3-[4,5-Dimethoxy-2-[[4-methoxy-3-(phenylmethoxy)phenyl]carbonyl]phenyl]pentan-2-one 618056-36-3P, 3-[2-[(3-Hydroxy-4-methoxyphenyl)carbonyl]-4,5-dimethoxyphenyl]pentan-2-one 618056-39-6P, 3-[4-Benzyloxy-5-methoxy-2-[(3,4-dimethoxyphenyl)carbonyl]phenyl]pentan-2-one 697754-57-7P, 3-[2-[(3,4-Dimethoxyphenyl)carbonyl]-4-hydroxy-5-methoxyphenyl]pentan-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzodiazepines for the treatment of neutropenia.)

RN 618056-34-1 CAPLUS
CN 2-Pentanone, 3-[4,5-dimethoxy-2-[4-methoxy-3-(phenylmethoxy)benzoyl]phenyl]- (CA INDEX NAME)



RN 618056-36-3 CAPLUS
CN 2-Pentanone, 3-[2-(3-hydroxy-4-methoxybenzoyl)-4,5-dimethoxyphenyl]- (CA INDEX NAME)



RN 618056-39-6 CAPLUS
CN 2-Pentanone, 3-[2-(3,4-dimethoxybenzoyl)-5-methoxy-4-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 697754-57-7 CAPLUS
CN 2-Pentanone, 3-[2-(3,4-dimethoxybenzoyl)-4-hydroxy-5-methoxyphenyl]- (CA INDEX NAME)



L52 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:326400 CAPLUS Full-text
DOCUMENT NUMBER: 139:374215
TITLE: Synthesis and cytotoxic activity of 1,3-benzodioxole derivatives. Note II
AUTHOR(S): Micale, Nicola; Zappala, Maria; Grasso, Silvana
CORPORATE SOURCE: Dipartimento Farmaco-Chimico, Universita di Messina, Messina, 98168, Italy
SOURCE: Farmaco (2003), 58(5), 351-355
CODEN: FRMCE8; ISSN: 0014-827X
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:374215
ED Entered STN: 29 Apr 2003
AB A series of 1,3-benzodioxoles (2-12) were synthesized and evaluated for their in vitro ability to inhibit the growth of three human tumor cell lines. No cytotoxic effects were noticed with any of the test compds. at a concentration of 10-4 M.
IT 132813-95-7P 197369-12-3P 501328-34-3P
623944-58-1P 623944-59-2P 623944-65-0P
623944-66-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and cytotoxic activity of 1,3-benzodioxole derivs.)
RN 132813-95-7 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-benzoyl-, methyl ester (CA INDEX NAME)



RN 197369-12-3 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-fluorobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 501328-34-3 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-aminobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 623944-58-1 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-chlorobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 623944-59-2 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-aminobenzoyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 623944-65-0 CAPLUS
CN 1,3-Benzodioxole-5-acetamide, N-methyl-6-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)



RN 623944-66-1 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-nitrobenzoyl)-, hydrazide (9CI) (CA INDEX NAME)



IT 197369-14-5P 209851-94-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and cytotoxic activity of 1,3-benzodioxole derivs.)
RN 197369-14-5 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-nitrobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 209851-94-5 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-nitrobenzoyl)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:907951 CAPLUS Full-text
DOCUMENT NUMBER: 138:237975
TITLE: Synthesis and antitumor activity of 1,3-benzodioxole derivatives
AUTHOR(S): Micale, Nicola; Zappala, Maria; Grasso, Silvana
CORPORATE SOURCE: Dipartimento farmaco-chimico, universita di Messina, Messina, 98168, Italy
SOURCE: Farmaco (2002), 57(10), 853-859
CODEN: FRMCE8; ISSN: 0014-827X
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:237975
ED Entered STN: 01 Dec 2002
GI



AB A series of 1,3-benzodioxoles was synthesized and evaluated for their in vitro antitumor activity against human tumor cell lines. Some derivs. exhibited tumor growth inhibition activity. In particular, 6-(4-aminobenzoyl)-1,3-benzodioxole-5-acetic acid Me ester (I), the most active compound of the series, possesses a significant growth inhibitory activity on 52 cell lines at concns. ranging from 10-7 to 10-5 M.
IT 197369-14-5P 433716-67-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of a series of 1,3-benzodioxoles from 1,3-benzodioxole-5-acetonitrile and evaluation of their antitumor activity)
RN 197369-14-5 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-nitrobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 433716-67-7 CAPLUS
CN 2-Propanone, 1-[6-(4-nitrobenzoyl)-1,3-benzodioxol-5-yl]- (9CI) (CA INDEX NAME)



IT 501328-34-3P 501328-36-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of a series of 1,3-benzodioxoles from 1,3-benzodioxole-5-acetonitrile and evaluation of their antitumor activity)
RN 501328-34-3 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-aminobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 501328-36-5 CAPLUS
CN 2-Propanone, 1-[6-(4-aminobenzoyl)-1,3-benzodioxol-5-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:401648 CAPLUS Full-text
DOCUMENT NUMBER: 133:43507
TITLE: Preparation of a (naphthyridinylethoxy)dibenzocycloheptaneacetic acid as a vitronectin receptor antagonist
INVENTOR(S): Miller, William H.; Manley, Peter J.
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033838	A1	20000615	WO 1999-US28662	19991203
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 482673	B	20020411	TW 1999-88120752	19991129
CA 2353415	A1	20000615	CA 1999-2353415	19991203
EP 1146874	A1	20011024	EP 1999-960647	19991203
EP 1146874	B1	20040922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9915879	A	20020213	BR 1999-15879	19991203
TR 200101654	T2	20020321	TR 2001-200101654	19991203
HU 200104804	A2	20020529	HU 2001-4804	19991203
AU 754408	B2	20021114	AU 2000-17502	19991203
JP 2003523931	T	20030812	JP 2000-586330	19991203
NZ 511876	A	20040227	NZ 1999-511876	19991203
AT 277043	T	20041015	AT 1999-960647	19991203
PT 1146874	T	20050228	PT 1999-960647	19991203
ES 2229798	T3	20050416	ES 1999-960647	19991203
AP 1534	A	20060228	AP 2001-2156	19991203
W: GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZW				
IN 2001MN00593	A	20050304	IN 2001-MN593	20010525
ZA 2001004398	A	20020529	ZA 2001-4398	20010529
NO 2001002732	A	20010801	NO 2001-2732	20010601
NO 318895	B1	20050518		
US 6495560	B1	20021217	US 2001-857316	20010712
HK 1042037	A1	20050729	HK 2002-101522	20020227
PRIORITY APPLN. INFO.:			US 1998-110903P P	19981204
			WO 1999-US28662 W	19991203

ED Entered STN: 16 Jun 2000
AB Et (S)-10-,11-dihydro-3-hydroxy-5H-dibenzo[a,d]cycloheptene-10-acetate was etherified by 2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethanol (preparation each given) and the product saponified to give (S)-10,11-dihydro-3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid (I). Data for biol. activity of I were given.
IT 77605-57-3P 210485-72-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of a (naphthyridinylethoxy)dibenzocycloheptaneacetic acid as a vitronectin receptor antagonist)
RN 77605-57-3 CAPLUS
CN Benzeneacetic acid, 2-benzoyl-4-methoxy- (9CI) (CA INDEX NAME)



RN 210485-72-6 CAPLUS
CN Butanedioic acid, [2-(3-methoxybenzoyl)phenyl]-, 4-ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:659355 CAPLUS Full-text
DOCUMENT NUMBER: 131:286273
TITLE: Preparation of hydroxyphenoxypropylnaphthylethylamines, methoxyphenylethylaminophenoxypropanols, and related compounds as calcilytics.
INVENTOR(S): Bhatnagar, Pradip Kumar; Burgess, Joelle Lorraine; Callahan, James Francis; Calvo, Raul Rolando; Del Mar, Eric G.; Lago, Maria Amparo; Nguyen, Thomas The
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA; NPS Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951569	A1	19991014	WO 1999-US7722	19990408
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2327279	A1	19991014	CA 1999-2327279	19990408
AU 9934819	A	19991025	AU 1999-34819	19990408
AU 752389	B2	20020919		
TR 200002896	T2	20010122	TR 2000-200002896	19990408
EP 1070048	A1	20010124	EP 1999-916516	19990408
EP 1070048	B1	20050831		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
HU 200101346	A2	20010828	HU 2001-1346	19990408
BR 9909486	A	20011106	BR 1999-9486	19990408
ZA 200005369	A	20011218	ZA 2000-5369	19990408
JP 2002510671	T	20020409	JP 2000-542291	19990408
NZ 507288	A	20030530	NZ 1999-507288	19990408
AP 1271	A	20040421	AP 2000-1931	19990408
W: GH, GM, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZW				
AT 303358	T	20050915	AT 1999-916516	19990408
ES 2247795	T3	20060301	ES 1999-916516	19990408
NO 2000005006	A	20001004	NO 2000-5006	20001004
US 6395919	B1	20020528	US 2000-647793	20001005
IN 2000MN00483	A	20050318	IN 2000-MN483	20001009
BG 104916	A	20010629	BG 2000-104916	20001107
HK 1034243	A1	20060421	HK 2001-104722	20010709
PRIORITY APPLN. INFO.:			US 1998-81093P P	19980408
			WO 1999-US7722 W	19990408

OTHER SOURCE(S): MARPAT 131:286273
ED Entered STN: 15 Oct 1999
GI



AB Title compds. [I; Y1 = bond, (O- or alkyl-substituted) alkylene, alkenylene; Y2 = (alkyl- or haloalkyl-substituted) methylene; Y3 = bond, O, S, imino, alkyleneoxy, alkylenethio, alkyleneimino; R3, R4 = Me, Et; R3R4C = cyclopropyl; R5 = (fused) (substituted) aryl; G = bond, CHR6, CR6; R6 = H, OH, O; R7 = H, OH, alkoxy; R8 = H, alkyl; R7R8 = O; A, B = bond, CH2, NH, O, S, CO; AB = CH:CH, C.tplbond.C; X1, X5 = H, halo, cyano, NO2, alkyl, cycloalkyl, arylmethyl, heteroarylmethyl; X2-X4 = H, halo, alkoxy, aryloxy, heteroaryloxy, arylmethyl, heteroarylmethyl, arylcarbonyl, heteroarylcarbonyl, etc.; with provisos], were prepared as calcium receptor antagonists for treatment of abnormal bone or mineral homeostasis (no data). Thus, (R)-4-[2-phenyl-2(RS)-(methoxycarbonyl)ethyl]phenoxyglycidol (preparation given), 4-methoxyphenyl-1,1-dimethylethylamine, and EtNH2 were refluxed 24 h in EtOH to give (R)-1-[1,1-dimethyl-2-(4- methoxyphenyl)ethylamino]-3-[4-(2-phenyl-2-(RS)-methoxycarbonylethyl)phenoxy]propan-2-ol hydrochloride.
IT 77605-57-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxyphenoxypropylnaphthylethylamines, methoxyphenylethylaminophenoxypropanols, and related compds. as calcilytics)

RN 77605-57-3 CAPLUS
CN Benzeneacetic acid, 2-benzoyl-4-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:417842 CAPLUS Full-text
DOCUMENT NUMBER: 125:76353
TITLE: Inhibitors of farnesyl-protein transferase
INVENTOR(S): Stokker, Gerald E.; Graham, Samuel L.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA; Stokker, Gerald, E.; Graham, Samuel, L.
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9610011	A1	19960404	WO 1995-US12321	19950925
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5523456	A	19960604	US 1994-315046	19940929
CA 2201351	A1	19960404	CA 1995-2201351	19950925
AU 9536426	A	19960419	AU 1995-36426	19950925
AU 689651	B2	19980402		
EP 787123	A1	19970806	EP 1995-933957	19950925
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10506898	T	19980707	JP 1996-511981	19950925
PRIORITY APPLN. INFO.:			US 1994-315046 A2	19940929
			WO 1995-US12321 W	19950925

ED Entered STN: 17 Jul 1996
AB The present invention comprises analogs of the CAAX motif of the protein Ras that is modified by farnesylation in vivo. These CAAX analogs inhibit the farnesylation of Ras. Furthermore, these CAAX analogs differ from those previously described as inhibitors of Ras farnesyl transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependant chemical reactions, such as rapid auto-oxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compns. containing these farnesyl transferase inhibitors and methods for their production

IT 178449-02-0P 178449-18-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of analogs of CAAX motif of protein Ras for inhibiting Ras farnesyl-transferase and for treating cancer)
RN 178449-02-0 CAPLUS
CN L-Methionine, N-[N-[2-[[(2-benzoylphenyl)acetyl]amino]-4-methylpentyl]-N-(1-naphthalenylmethyl)glycyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178449-18-8 CAPLUS
CN L-Methionine, N-[N-[2-[[(2-benzoylphenyl)acetyl]amino]-4-methylpentyl]-N-(1-naphthalenylmethyl)glycyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



NARROWER STRUCTURE SEARCH

=> fil reg; d stat que l42; fil capl
FILE 'REGISTRY' ENTERED AT 15:09:42 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3
DICTIONARY FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

L8 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L11 625 SEA FILE=REGISTRY SSS FUL L8
L35 STR



VPA 19-9/10/11/12 U
VPA 20-1/2/4/5/6 U
NODE ATTRIBUTES:
NSPEC IS RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L38 STR



VPA 18-9/10/11/12 U
VPA 19-9/10/11/12 U
NODE ATTRIBUTES:
NSPEC IS RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L39 STR



```
VPA 20-1/2/4/5/6 U
VPA 21-1/2/4/5/6 U
NODE ATTRIBUTES:
NSPEC   IS RC     AT  16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  20

STEREO ATTRIBUTES: NONE
L42         151 SEA FILE=REGISTRY SUB=L11 SSS FUL (L35 OR L38 OR L39)

100.0% PROCESSED     193 ITERATIONS                          151 ANSWERS
SEARCH TIME: 00.00.01



FILE 'CAPLUS' ENTERED AT 15:09:42 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Jun 2007  VOL 146 ISS 26
FILE LAST UPDATED: 14 Jun 2007  (20070614/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> => d que nos 143; s l43 not l44,152
L8              STR
L11         625 SEA FILE=REGISTRY SSS FUL L8
L35             STR
L38             STR
L39             STR
L42         151 SEA FILE=REGISTRY SUB=L11 SSS FUL (L35 OR L38 OR L39)
L43           5 SEA FILE=CAPLUS ABB=ON  L42


L53           3 L43 NOT (L44 OR L52)

=> d ibib ed abs hitstr 1-3; fil hom
```



```
L53  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:408217  CAPLUS  Full-text
                            Correction of: 2005:155220
DOCUMENT NUMBER:          143:266757
                            Correction of: 142:197771
TITLE:                    Product class 5: isoquinolines
AUTHOR(S):                Alvarez, M.; Joule, J. A.
CORPORATE SOURCE:         Germany
SOURCE:                   Science of Synthesis (2005), 15, 661-838
                          CODEN: SSCYJ9
PUBLISHER:                Georg Thieme Verlag
DOCUMENT TYPE:            Journal; General Review
LANGUAGE:                 English
ED   Entered STN:  13 May 2005
AB   A review primarily covering methods of preparation of isoquinolines via
     cyclization, ring transformations or substituent modification. Isoquinoline 2-
     oxides and isoquinolinium salts are also included.
IT   180072-41-7
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of isoquinolines and analogs via cyclization, ring
        transformations or substituent modifications)
RN   180072-41-7  CAPLUS
CN   Benzeneacetamide, N-[(1R)-2-hydroxy-1-phenylethyl]-4,5-dimethoxy-2-(3,4,5-
     trimethoxybenzoyl)- (9CI)  (CA INDEX NAME)

Absolute stereochemistry.
```



```
L53  ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         1996:376527  CAPLUS  Full-text
DOCUMENT NUMBER:          125:167761
TITLE:                    Asymmetric synthesis. XLI. Totally stereoselective
                          synthesis of 1,3-disubstituted tetrahydroisoquinolines
                          via the CN(R,S) method
AUTHOR(S):                Gosmann, Grace; Guillaume, Dominique; Husson,
                          Henri-Philippe
CORPORATE SOURCE:         Lab. Chimie Therapeutique associe CNRS, Univ. R.
                          Descartes, Paris, 75270, Fr.
SOURCE:                   Tetrahedron Letters (1996), 37(25), 4369-4372
                          CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER:                Elsevier
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
OTHER SOURCE(S):          CASREACT 125:167761
ED   Entered STN:  28 Jun 1996
GI
```




```
AB   Optically active cis- or trans- 1,3-disubstituted tetrahydroisoquinolines 3-R-
     or 3S-I (R = Me, CH2Ph) can be prepared selectively from the same oxazolidine
     II.  This latter is easily obtained from keto-acid III and (R)-(-
     )phenylglycinol.
IT   180072-41-7P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (stereoselective preparation of isoquinolines)
RN   180072-41-7  CAPLUS
CN   Benzeneacetamide, N-[(1R)-2-hydroxy-1-phenylethyl]-4,5-dimethoxy-2-(3,4,5-
     trimethoxybenzoyl)- (9CI)  (CA INDEX NAME)

Absolute stereochemistry.
```



```
L53  ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         1974:108242  CAPLUS  Full-text
DOCUMENT NUMBER:          80:108242
TITLE:                    Tetracycline studies. IV. Novel cyclizations through
                          benzophenone carbanions, including a new synthesis of
                          anthraquinones
AUTHOR(S):                Hassall, Cedric H.; Morgan, Barry A.
CORPORATE SOURCE:         Dep. Chem., Univ. Coll. Swansea, Swansea, UK
SOURCE:                   Journal of the Chemical Society, Perkin Transactions
```



```
                          1:  Organic and Bio-Organic Chemistry (1972-1999)
                          (1973), (23), 2853-61
                          CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
ED   Entered STN:  12 May 1984
GI   For diagram(s), see printed CA Issue.
AB   2,3,5-Me(MeO)2C6H2CH2CN with 2,4,6,3-(MeO)3(MeO2C)C6HCO2H in (F3CCO)2O gave
     71% benzophenone (I) which with NaOMe in DMF gave 95% anthrol (II). II with
     H2O2 and NaOH gave 96% 1,3,6,8-tetramethoxy-2-(methoxycarbonyl)-5-
     methylanthraquinone which gave the 6-methylpretetramid analog (III) in 3
     steps.  Other anthraquinones including emodin and physcion were prepared
     similarly.
IT   52344-90-8P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (preparation of)
RN   52344-90-8  CAPLUS
CN   Benzeneacetamide, N,2-bis(2,6-dimethoxybenzoyl)-3,5-dimethoxy- (9CI)  (CA
     INDEX NAME)
```



```
FILE 'HOME' ENTERED AT 15:10:23 ON 15 JUN 2007
```

SEARCH HISTORY

=> d stat que l42; d his nofile
L8 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L11 625 SEA FILE=REGISTRY SSS FUL L8
L35 STR



VPA 19-9/10/11/12 U
VPA 20-1/2/4/5/6 U
NODE ATTRIBUTES:
NSPEC IS RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L38 STR



VPA 18-9/10/11/12 U
VPA 19-9/10/11/12 U
NODE ATTRIBUTES:
NSPEC IS RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L39 STR



VPA 20-1/2/4/5/6 U
VPA 21-1/2/4/5/6 U
NODE ATTRIBUTES:
NSPEC IS RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L42 151 SEA FILE=REGISTRY SUB=L11 SSS FUL (L35 OR L38 OR L39)

100.0% PROCESSED 193 ITERATIONS 151 ANSWERS
SEARCH TIME: 00.00.01

(FILE 'HOME' ENTERED AT 14:40:53 ON 15 JUN 2007)

FILE 'REGISTRY' ENTERED AT 14:41:33 ON 15 JUN 2007

L1 STR
L2 5 SEA SSS SAM L1

FILE 'ZCAPLUS' ENTERED AT 14:44:51 ON 15 JUN 2007
L3 2 SEA ABB=ON L2
D SCAN TI

FILE 'REGISTRY' ENTERED AT 14:45:22 ON 15 JUN 2007
L4 STR L1
L5 5 SEA SSS SAM L4
L6 STR L4
L7 11 SEA SSS SAM L6
L8 STR L6
L9 33 SEA SSS SAM L8
L10 5028 SEA SSS FUL L8 EXTEND
L11 625 SEA SSS FUL L8
SAVE TEMP L11 HAV415FULL/A

FILE 'ZCAPLUS' ENTERED AT 14:47:02 ON 15 JUN 2007
L12 283 SEA ABB=ON L11

FILE 'REGISTRY' ENTERED AT 14:48:19 ON 15 JUN 2007
L13 STR L8
L14 STR L4
L15 STR L4
L16 22 SEA SUB=L11 SSS SAM (L13 OR L14 OR L15)

FILE 'STNGUIDE' ENTERED AT 14:52:39 ON 15 JUN 2007

FILE 'ZCAPLUS' ENTERED AT 14:52:47 ON 15 JUN 2007
L17 23 SEA ABB=ON L16

FILE 'REGISTRY' ENTERED AT 14:53:43 ON 15 JUN 2007
L18 STR L4
L19 5 SEA SUB=L11 SSS SAM L18
L20 5 SEA ABB=ON L5 AND L19

FILE 'CAPLUS' ENTERED AT 14:54:46 ON 15 JUN 2007
E US2005-561415/APPS
L21 1 SEA ABB=ON US2005-561415/AP
D SCAN
SEL RN

FILE 'REGISTRY' ENTERED AT 14:55:14 ON 15 JUN 2007
L22 412 SEA ABB=ON (100-09-4/BI OR 100-52-7/BI OR 103-76-4/BI OR 10365-98-7/BI OR 106-95-6/BI OR 109-01-3/BI OR 109-70-6/BI OR 109-83-1/BI OR 109-85-3/BI OR 109384-19-2/BI OR 110-87-2/BI OR 110-91-8/BI OR 111-42-2/BI OR 111-95-5/BI OR 111373-03-6/BI OR 123-11-5/BI OR 126495-72-5/BI OR 13205-46-4/BI OR 13205-48-6/BI OR 13889-98-0/BI OR 141699-59-4/BI OR 16015-71-7/BI OR 1694-92-4/BI OR 17739-45-6/BI OR 18226-11-4/BI OR 183322-16-9/BI OR 183500-94-9/BI OR 189205-49-0/BI OR 19344-29-7/BI OR 20173-04-0/BI OR 208245-69-6/BI OR 214360-76-6/BI OR 2328-12-3/BI OR 290328-55-1/BI OR 3240-94-6/BI OR 329-15-7/BI OR 330-12-1/BI OR 331-64-6/BI OR 34328-61-5/BI OR 34750-64-6/BI OR 34841-06-0/BI OR 3485-05-0/BI OR 351-54-2/BI OR 3647-69-6/BI OR 3731-52-0/BI OR 38256-93-8/BI OR 39216-84-7/BI OR 3943-89-3/BI OR 39546-32-2/BI OR 40137-22-2/BI OR 40499-83-0/BI OR 40807-61-2/BI OR 4138-26-5/BI OR 4439-22-9/BI OR 456-22-4/BI OR 4606-65-9/BI OR 4724-10-1/BI OR 4753-75-7/BI OR 4837-20-1/BI

OR 488-93-7/BI OR 51254-17-2/BI OR 527-72-0/BI OR 5332-73-0/BI OR 53617-35-9/BI OR 5407-04-5/BI OR 54093-33-3/BI OR 555-16-8/BI OR 586-38-9/BI OR 59817-32-2/BI OR 621-51-2/BI OR 622-26-4/BI OR 627-30-5/BI OR 645-08-9/BI OR 6457-49-4/BI OR 6482-24-2/BI OR 65-85-0/BI OR 6859-99-0/BI OR 68832-13-3/BI OR 7663-77-6/BI OR 76903-88-3/BI OR 819810-73-6/BI OR 819810-75-8/BI OR 819810-77-0/BI OR 819810-79-2/BI OR 819810-81-6/BI OR 819810-82-7/BI OR 819810-83-8/BI OR 819810-85-0/BI OR 819810-87-2/BI OR 819810-89-4/BI OR 819810-90-7/BI OR 819810-91-8/BI OR 819810-92-9/BI OR 819810-93-0/BI OR 819810-94-1/BI OR 819810-95-2/BI OR 819810-96-3/BI OR 819810-97-4/BI OR 819810-98-5/BI OR 819810-99-6/BI OR 819811-00-2/BI OR 819811-01-3/BI OR 819811-02-4/BI OR 819811-03-5/BI OR 819811-04-6/BI OR 819811-05-7/BI OR 819811-06-8/BI OR 819811-07-9/BI OR 819811-08-0/BI OR 819811-09-1/BI OR 819811-10-4/BI OR 819811-11-5/BI OR 819811-12-6/BI OR 819811-13-7/BI OR 819811-14-8/BI OR 819811-15-9/BI OR 819811-16-0/BI OR 819811-17-1/BI OR 819811-18-2/BI OR 819811-19-3/BI OR 819811-
L23 220 SEA ABB=ON L22 AND L11
L24 254 SEA ABB=ON L11 AND N/ELS

FILE 'ZCAPLUS' ENTERED AT 14:57:24 ON 15 JUN 2007
L25 74 SEA ABB=ON L24

FILE 'REGISTRY' ENTERED AT 14:57:42 ON 15 JUN 2007
L26 191 SEA ABB=ON L24 AND 5<O

FILE 'ZCAPLUS' ENTERED AT 14:57:48 ON 15 JUN 2007
L27 39 SEA ABB=ON L26

FILE 'REGISTRY' ENTERED AT 14:58:02 ON 15 JUN 2007
L28 52 SEA ABB=ON L26 NOT L22
L29 15175 SEA ABB=ON NITROBENZ
L30 52 SEA ABB=ON L28 NOT L29
L31 0 SEA ABB=ON L28 AND L29
L32 118258 SEA ABB=ON NITROBENZ?
L33 11 SEA ABB=ON L28 NOT L32
D SCAN

FILE 'ZCAPLUS' ENTERED AT 15:01:47 ON 15 JUN 2007
L34 12 SEA ABB=ON L33

FILE 'REGISTRY' ENTERED AT 15:02:33 ON 15 JUN 2007
L35 STR L4
L36 9 SEA SUB=L11 SSS SAM L35
L37 0 SEA ABB=ON L36 NOT L22
L38 STR L4
L39 STR L4
L40 9 SEA SUB=L11 SSS SAM (L35 OR L38 OR L39)
D QUE
L41 193 SEA SUB=L11 SSS FUL (L35 OR L38 OR L39) EXTEND
L42 151 SEA SUB=L11 SSS FUL (L35 OR L38 OR L39)
SAVE TEMP L42 HAV415SUB/A

FILE 'CAPLUS' ENTERED AT 15:05:38 ON 15 JUN 2007
L43 5 SEA ABB=ON L42
L44 1 SEA ABB=ON L21 OR (L21 AND L43)
D SCAN
L45 29025 SEA ABB=ON HEAT SHOCK/OBI OR HSP90/OBI OR HSP/OBI
L46 283 SEA ABB=ON L11
L47 283 SEA ABB=ON L11

```
L48           1 SEA ABB=ON  L47 AND L45
L49      166137 SEA ABB=ON  ANTITUMOR AGENTS/CT
L50      484200 SEA ABB=ON  NEOPLAS7/OBI
L51           8 SEA ABB=ON  L47 AND (L49 OR L50)

     FILE 'CAPLUS' ENTERED AT 15:08:14 ON 15 JUN 2007
               D QUE NOS L44
               D IBIB ED ABS HITSTR L44

     FILE 'REGISTRY' ENTERED AT 15:08:48 ON 15 JUN 2007
               D STAT QUE L11

     FILE 'CAPLUS' ENTERED AT 15:08:48 ON 15 JUN 2007
               D QUE NOS L48
               D QUE NOS L51
L52           7 SEA ABB=ON  (L48 OR L51) NOT L44
               D IBIB ED ABS HITSTR 1-7

     FILE 'REGISTRY' ENTERED AT 15:09:42 ON 15 JUN 2007
               D STAT QUE L42

     FILE 'CAPLUS' ENTERED AT 15:09:42 ON 15 JUN 2007
               D QUE NOS L43
L53           3 SEA ABB=ON  L43 NOT (L44 OR L52)
               D IBIB ED ABS HITSTR 1-3

     FILE 'HOME' ENTERED AT 15:10:23 ON 15 JUN 2007
               D STAT QUE L42

=>
```

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	5	("7115651" "7074770").pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 13:36
S2	6	"561415".ap.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/13 08:55
S3	2	"7022700".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/20 17:27
S4	7	"309527".ap.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/20 17:32
S5	2	"6495560".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/20 17:33
S6	2	"5523456".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/20 17:33